Acorda Therapeutics Company Profile (NASDAQ:ACOR)

Analyst Ratings

Consensus Ratings for Acorda Therapeutics (NASDAQ:ACOR) (?)
Ratings Breakdown: 1 Sell Rating(s), 5 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $39.75 (48.82% upside)

Analysts' Ratings History for Acorda Therapeutics (NASDAQ:ACOR)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016AegisBoost Price TargetBuy$40.00 -> $52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2016Leerink SwannReiterated RatingHold$31.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016Cowen and CompanyReiterated RatingOutperform$65.00 -> $60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016Evercore ISIReiterated RatingHold$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Goldman Sachs Group Inc.Initiated CoverageSell$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Stifel NicolausLower Price TargetBuy$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/11/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/31/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2015Canaccord GenuityReiterated RatingHold$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2015MLV & Co.Set Price TargetBuy$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/22/2015Piper Jaffray Cos.Initiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/13/2015Citigroup Inc.Reiterated RatingHold$46.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2015Royal Bank Of CanadaSet Price TargetBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/31/2014FBR & CoReiterated RatingOutperform$57.00 -> $59.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2014MKM PartnersBoost Price TargetNeutral$31.50 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Acorda Therapeutics (NASDAQ:ACOR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016Q216$0.18$128.33 millionListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q116$0.08$0.07$115.36 million$115.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2016Q415$0.22$0.28$128.24 million$130.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2015Q315$0.15$0.31$115.52 million$148.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215$0.17$0.31$110.84 million$113.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115$0.03($0.02)$100.20 million$99.85 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q414$0.14$0.46$110.80 million$117.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314$0.05$0.28$94.70 million$106.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214$0.15$0.42$91.40 million$97.13 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q114$0.09$0.21$81.30 million$80.52 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2014Q413$0.18$0.32$89.96 million$92.59 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313$0.13$0.36$90.01 million$84.92 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013$0.09$0.25$82.57 million$87.05 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013$0.20$0.09$80.77 million$71.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2013Q4 2012$0.15$0.24$78.90 million$81.47 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2012Q312$0.10$0.38$75.20 million$77.44 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2012$0.27$0.27ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012$0.27$0.36ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2012$0.24$0.40ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2011$0.82$0.47ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2011$0.10$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011$0.17($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2011$0.17$0.09ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Acorda Therapeutics (NASDAQ:ACOR)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Acorda Therapeutics (NASDAQ:ACOR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Acorda Therapeutics (NASDAQ:ACOR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/22/2016David LawrenceInsiderSell500$25.09$12,545.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2016Steven M RauscherDirectorSell1,086$27.83$30,223.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016Andrew A HindmanInsiderSell4,860$26.11$126,894.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Lorin RandallDirectorSell1,488$28.68$42,675.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Ian F. SmithDirectorSell13,231$41.85$553,717.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Jane WasmaninsiderSell10,751$43.10$463,368.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2015Lauren M. SabellainsiderSell7,113$42.04$299,030.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Jane WasmanInsiderSell817$42.00$34,314.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2015David LawrenceinsiderSell39,026$40.63$1,585,626.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Lauren M. SabellainsiderSell14,229$40.00$569,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Enrique J CarrazanaInsiderSell7,218$38.08$274,861.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Ron CohenCEOSell11,850$38.08$451,248.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015Andrew BlightinsiderSell32,500$30.87$1,003,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Michael W. RogersCFOSell5,700$30.24$172,368.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Jane WasmaninsiderSell3,750$31.75$119,062.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Ron CohenCEOSell135,000$28.03$3,784,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Andrew BlightinsiderSell13,085$31.30$409,560.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Andrew A HindmanInsiderSell4,779$29.82$142,509.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Enrique J CarrazanaInsiderSell97,993$42.21$4,136,284.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014David LawrenceInsiderSell27,109$40.11$1,087,341.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014John P KelleyDirectorSell10,000$40.00$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014David LawrenceInsiderSell8,898$35.60$316,768.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Lauren M SabellaVPSell3,242$35.58$115,350.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Michael W RogersCFOSell230$35.58$8,183.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Ron CohenCEOSell34,394$35.59$1,224,082.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Michael W RogersCFOSell5,700$33.10$188,670.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014Jane WasmanInsiderSell3,750$34.13$127,987.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Jane WasmanInsiderSell14,923$36.00$537,228.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Jane WasmanInsiderSell14,923$33.00$492,459.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Lauren SabellaVPSell8,797$31.81$279,832.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Enrique CarrazanaInsiderSell1,640$33.56$55,038.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2013Enrique J CarrazanaInsiderSell3,333$32.38$107,922.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2013Jane WasmanInsiderSell3,750$35.74$134,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Ron CohenCEOSell149,000$34.10$5,080,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/2/2013John KelleyDirectorSell15,000$38.00$570,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/19/2013Andrew BlightInsiderSell19,296$37.82$729,774.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2013Ron CohenCEOSell11,000$34.15$375,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2013Sandra Phd PanemDirectorSell10,000$33.80$338,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2012Lauren M SabellaVPSell4,364$24.58$107,267.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012Andrew BlightInsiderSell7,200$24.20$174,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012David LawrenceCFOSell9,313$24.21$225,467.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012Ron CohenCEOSell16,407$24.22$397,377.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2012Sandra Phd PanemDirectorSell22,569$24.12$544,364.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Acorda Therapeutics (NASDAQ:ACOR)
DateHeadline
07/26/16 02:19 PMAcorda Therapeutics, Inc. (NASDAQ:ACOR) To Report June 2016 Results - The Voice Registrar
07/26/16 02:00 PM[$$] Three Biotech Q2 Reports Hold Potential -
07/22/16 02:17 PMAcorda Therapeutics Inc. (ACOR) is Trading Higher on Unusual Volume for July 20 - Equities.com
07/22/16 10:27 AMAcorda Therapeutics Inc. (ACOR) is Trading Higher on Unusual Volume for July 20
07/21/16 02:17 PMIncreased Stock Volatility Watch: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Engelwood Daily
07/21/16 02:17 PMAcorda Therapeutics, Inc. (NASDAQ:ACOR) Current Analyst Ratings - Fiscal Standard
07/21/16 02:17 PMAcorda Therapeutics Inc. (ACOR) Jumps 6.96% on July 20 - Equities.com
07/21/16 10:36 AMTreatments for Syndromes of Progressive Ataxia and Weakness Disorders : Opportunities and Forecasts to 2020
07/20/16 08:55 PMAcorda Therapeutics Inc. (ACOR) Jumps 6.96% on July 20
07/20/16 02:34 PMStock Moving Lower for the Month; Investor Update on Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Engelwood Daily
07/20/16 02:34 PMShares Jumping Higher in Session: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - TGP
07/19/16 07:43 PMBiotie Therapies Oyj: ARBITRATORS APPOINTED FOR THE REDEMPTION PROCEEDINGS OF BIOTIE'S MINORITY SHARES
07/19/16 08:29 AMAcorda Therapeutics, Inc. (NASDAQ:ACOR): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/19/16 08:29 AMShares Lower on the Year Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Press Telegraph
07/19/16 08:29 AMAcorda Therapeutics (NASDAQ:ACOR) decreased -0.63%: Galena Biopharma Inc (NASDAQ:GALE), Broadridge ... - KC Register
07/19/16 01:04 AMARBITRATORS APPOINTED FOR THE REDEMPTION PROCEEDINGS OF BIOTIE'S MINORITY SHARES - [GlobeNewswire] - BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 19 July 2016, at 9.00 a.m. (EET) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH ...
07/18/16 07:04 AMStrong Sell Calls For Acorda Therapeutics, Inc. (NASDAQ:ACOR) At 0 - Investor Newswire
07/17/16 07:03 AMReview on Stock Valuation for: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - TGP
07/16/16 10:41 AMShares Experiencing a Downtrend: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - TGP
07/16/16 10:41 AMAcorda Therapeutics Incorporated (NASDAQ:ACOR) Short Interest Increased By 5.36% - Consumer Eagle
07/15/16 12:52 PMCrowd Rating and Earnings Recap for Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Telanagana Press
07/15/16 12:52 PMAcorda Therapeutics Inc (NASDAQ:ACOR) near 52-week low, short interest ramping up - Street Report
07/14/16 07:46 PMAcorda Therapeutics, Inc. (NASDAQ:ACOR) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/14/16 02:17 PMShort Data Recap for: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Engelwood Daily
07/13/16 02:18 PMAcorda Therapeutics Incorporated (NASDAQ:ACOR) Shorted Shares Increased 5.36% After Market Selling - Press Telegraph
07/13/16 02:18 PMAcorda Therapeutics Inc Stock Momentum Hits Extreme Weakness - CML News
07/13/16 08:29 AMCoverage Initiated on Select Biotech Stocks -
07/12/16 02:18 PMAcorda Therapeutics, Inc. (NASDAQ:ACOR) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 02:18 PMStock Down on the Year Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Press Telegraph
07/12/16 02:18 PMTrading Performance and Target Watch for Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Press Telegraph
07/11/16 02:17 PMStock Volatility Focus for: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Engelwood Daily
07/11/16 07:04 AMIs $60 Within Reach For Acorda Therapeutics, Inc. (NASDAQ:ACOR)? - Investor Newswire
07/11/16 07:04 AMStock Performance Rundown on: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Press Telegraph
07/10/16 07:04 AMHow Many Acorda Therapeutics Inc (NASDAQ:ACOR)'s Analysts Are Bullish? - Engelwood Daily
07/08/16 02:18 PMWall Street Ratings and Target Price Views on Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Telanagana Press
07/07/16 02:17 PMShort Information Review for: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Engelwood Daily
07/07/16 02:17 PMStock Expected to Grow at an Accelerated Rate: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Telanagana Press
07/07/16 02:17 PMAcorda Therapeutics Inc.: Acorda to Host Conference Call to Discuss Second Quarter 2016 on July 28, 2016 - The Wall Street Transcript
07/07/16 10:12 AMForm 4 ACORDA THERAPEUTICS INC For: Jul 01 Filed by: BLANK BURKHARD
07/07/16 06:11 AMAcorda to Host Conference Call to Discuss Second Quarter 2016 on July 28, 2016 - [at noodls] - ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its second quarter 2016 financial results and pipeline updates on Thursday, July ...
07/06/16 08:00 PMAcorda Therapeutics, Inc. (NASDAQ:ACOR) Analyst Rating Update - Investor Newswire
07/06/16 02:17 PMForm 4 ACORDA THERAPEUTICS INC For: Jul 01 Filed by: BLANK BURKHARD - StreetInsider.com
07/06/16 07:04 AMStock Tracking Down This Month; Investor Alert on Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Engelwood Daily
07/06/16 07:04 AMStock Rating Watch and Earnings Insight for Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Press Telegraph
07/06/16 07:04 AMBroker Outlook For Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Fiscal Standard
07/04/16 07:04 AMAcorda Therapeutics Incorporated (NASDAQ:ACOR) Shorted Shares Increased By 5.36% - Press Telegraph
07/04/16 07:04 AMAcorda Therapeutics, Inc. (NASDAQ:ACOR) Broker Price Targets For The Coming Week - Fiscal Standard
07/03/16 02:17 PMAcorda Therapeutics, Inc. (NASDAQ:ACOR) Expected to Reach Highs Of $60 - Investor Newswire
07/03/16 02:17 PMShare Performance Recap for: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Press Telegraph
07/03/16 07:04 AMStock Valuation in Review: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Telanagana Press

Social

About Acorda Therapeutics

Acorda Therapeutics logoAcorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson's disease, chronic post-stroke walking deficits and migraine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ACOR
  • CUSIP: 00484M10
Key Metrics:
  • Previous Close: $25.91
  • 50 Day Moving Average: $25.75
  • 200 Day Moving Average: $29.71
  • P/E Ratio: 87.91
  • P/E Growth: 1.22
  • Market Cap: $1.22B
  • Beta: 1.5
  • Current Year EPS Consensus Estimate: $0.73 EPS
  • Next Year EPS Consensus Estimate: $0.85 EPS
Additional Links:
Acorda Therapeutics (NASDAQ:ACOR) Chart for Wednesday, July, 27, 2016